To verify this, we performed mTOR and Bcl‐2 loss‐of function experiments in U87‐TR and SF295‐TR cells to investigate whether the silencing of mTOR and Bcl‐2 in glioma cells could regulate the chemotherapy resistance of glioma cells in vitro. The gene discussed is MTOR; the disease is central nervous system cancer.